First trimester maternal serum placental protein 13 levels in singleton vs. Twin pregnancies with and without severe pre-eclampsia

Journal of Perinatal Medicine

Volumn 41, Issue 5, 2013, Pages 561-566

  Svirsky, Ran ^b   Meiri, Hamutal ^c,d   Herzog, Ayelet ^c   Kivity, Vered ^d   Cuckle, Howard ^e   Maymon, Ron ^a  

^a ASSAF HAROFEH MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c HY LABORATORIES LTD   (Israel)

^d TeleMarpe Ltd   (Israel)

^e Department of Medicine   (United States)

Author keywords

Placental protein 13; Pre eclampsia; Prediction; Serum biomarkers; Twins

Indexed keywords

PLACENTA PROTEIN; PLACENTA PROTEIN 13; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DELIVERY; DEMOGRAPHY; FEMALE; FERTILIZATION IN VITRO; FIRST TRIMESTER PREGNANCY; HUMAN; IMMUNOASSAY; ISRAEL; MAJOR CLINICAL STUDY; MATERNAL SERUM; PREECLAMPSIA; PREGNANCY OUTCOME; PRENATAL PERIOD; PRIORITY JOURNAL; PROTEIN ANALYSIS; RANK SUM TEST; TWIN PREGNANCY; TWINS;

ADOLESCENT; ADULT; BIOLOGICAL MARKERS; COHORT STUDIES; FEMALE; FERTILIZATION IN VITRO; GALECTINS; HUMANS; INFANT, NEWBORN; MIDDLE AGED; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY OUTCOME; PREGNANCY PROTEINS; PREGNANCY TRIMESTER, FIRST; PREGNANCY, TWIN; PROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

EID: 84888605255     PISSN: 03005577     EISSN: 16193997     Source Type: Journal    
DOI: 10.1515/jpm-2013-0011     Document Type: Article

References (32)

1. ACOG Committee on Obstetric Practice. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, 2002. American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet. 2002;77:67-75.
2. Akolekar R, Syngelaki A, Beta J, Kocylowski R, Nicolaides KH. Maternal serum placental protein 13 at 11-13 weeks of gestation in preeclampsia. Prenat Diagn. 2009;29:1103-8.
3. Balogh A, Pozsgay J, Matkó J, Dong Z, Kim CJ, Várkonyi T, et al. Placental protein 13 (PP13/Galectin-13) undergoes lipid raft-Associated subcellular redistribution in the syncytiotrophoblast in preterm preeclampsia and HELLP syndrome. Am J Obstet Gynecol. 2011;205:e1-14.
4. Bdolah Y, Lam C, Rajakumar A, Shivalingappa V, Mutter W, Sachs BP, et al. Twin pregnancy and the risk of preeclampsia: bigger placenta or relative ischemia? Am J Obstet Gynecol. 2008;198:428.e1-6.
5. Bujold E, Roberge S, Lacass Y, Bureau M, Audibert F, Marcoux S, et al. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-Analysis. Obstet Gynecol. 2010;116:402-14.
6. Calhoun KC, Barnhart KT, Elovitz MA, Srinivas SK. Evaluating the association between assisted conception and the severity of preeclampsia. ISRN Obstet Gynecol. 2011;2011:928592.
7. Caspi E, Raziel A, Sherman D, Arieli S, Bukovski I, Weinraub Z. Prevention of pregnancy-induced hypertension in twins by early administration of low-dose aspirin: a preliminary report. Am J Reprod Immunol. 1994;31:19-24.
8. Cetin I, Huppertz B, Burton G, Cuckle H, Gonen R, Lapaire O, et al. Pregenesys pre-eclampsia markers consensus meeting: What do we require from markers, risk assessment and model systems to tailor preventive strategies? Placenta. 2011;32(Suppl 1):S4-16.
9. Chafetz I, Kuhnreich I, Sammar M, Tal Y, Gibor Y, Meiri H, et al. First-trimester placental protein 13 screening for pre-eclampsia and intrauterine growth restriction. Am J Obstet Gynecol. 2007;197:35.e1-7.
10. Cuckle H. Screening for preeclampsia-lessons from aneuploidy screening. Placenta. 2011;32(Suppl 1):S42-8.
11. Dumoulin JC, Land JA, Van Montfoort AP, Nelissen EC, Coonen E, Derhaag JG, et al. Effect of in vitro culture of human embryos on birthweight of newborns. Hum Reprod. 2010; 25:605-12.
12. Gielen M, Lindsey PJ, Derom C, Loos RJ, Derom R, Nijhuis JG, et al. Curves of placental weights of live-born twins. Twin Res Hum Genet. 2006;9:664-72.
13. Giguere Y, Charland M, Bujold E, Bernard N, Grenier S, Rousseau F, et al. Combining biochemical and ultrasonographic markers in predicting preeclampsia: a systematic review. Clin Chem. 2010;56:361-5.
14. Gonen R, Shahar R, Grimpel YI, Chefetz I, Sammar M, Meiri H, et al. Placental protein 13 as an early marker for preeclampsia: a prospective longitudinal study. Br J Obstet Gynaecol. 2008:115;1465-72.
15. Grimpel YI, Kivity V, Cohen A, Meiri H, Sammar M, Gonen R, et al. Effects of calcium, magnesium, low-dose aspirin and low-molecular-weight heparin on the release of PP13 from placental explants. Placenta. 2011;32(Suppl 1):S55-64.
16. Hadlock FP, Shah YP, Kanon DJ, Lindsey JV. Fetal crown-rump length: reevaluation of relation to menstrual age (5-18 weeks) with high-resolution real-time US. Radiology. 1992;182:501-5.
17. Huppertz B, Sammar M, Chefetz I, Neumaier-Wagner P, Bartz C, Meiri H. Longitudinal determination of serum placental protein 13 during development of pre-eclampsia. Fetal Diagn Ther. 2008;24:230-6.
18. Khalil A, Cowans NJ, Spencer K, Goichman S, Meiri H, Harrington K. First-trimester markers for the prediction of preeclampsia in women with a-priori high risk. Ultrasound Obstet Gynecol. 2010;35:671-9.
19. Klein K, Mailath-Pokorny M, Elhenicky M, Schmid M, Zeisler H, Worda C. Mean, lowest, and highest pulsatility index of the uterine artery and adverse pregnancy outcome in twin pregnancies. Am J Obstet Gynecol. 2011;205:549.e1-7.
20. Koster MP, Wortelboer EJ, Stoutenbeek P, Visser GH, Schielen PC. Distributions of current and new first-trimester Down syndrome screening markers in twin pregnancies. Prenat Diagn. 2010;30:413-7.
21. Lindheimer MD, Taler SJ, Cunningham FG, American Society of Hypertension. ASH position paper: hypertension in pregnancy. J Clin Hypertens (Greenwich). 2009;11:214-25.
22. Muller F, Dreux S, Dupoizat H, Uzan S, Dubin MF, Oury JF, et al. Second-trimester Down syndrome maternal serum screening in twin pregnancies: impact of chorionicity. Prenat Diagn. 2003;23:331-5.
23. Noble PL, Snijders RJ, Abraha HD, Sherwood RA, Nicolaides KH. Maternal serum free beta-hCG at 10 to 14 weeks of gestation in trisomic twin pregnancies. Br J Obstet Gynaecol. 1997;104:741-3.
24. Orendi K, Gauster M, Moser G, Meiri H, Huppertz B. Effects of vitamins C and E, acetylsalicylic acid and heparin on fusion, beta-hCG and PP13 expression in BeWo cells. Placenta. 2010;31:431-8.
25. Publications Committee, Society for Maternal-Fetal Medicine, Sibai BM. Evaluation and management of severe preeclampsia before 34 weeks' gestation. Am J Obstet Gynecol. 2011;205:191-8.
26. Romero R, Kusanovic JP, Than NG, Erez O, Gotsch F, Espinoza J, et al. First-trimester maternal serum PP13 in the risk assessment for preeclampsia. Am J Obstet Gynecol. 2008;199:122:e1-11.
27. Santolaya-Forgas J, De Leon JA, Cullen Hopkins R, Castracane VD, Kauffman RP, Sifuentes GA. Low pregnancyassociated plasma protein-A at 10(+1) to 14(+6) weeks of gestation and a possible mechanism leading to miscarriage. Fetal Diagn Ther. 2004;19:456-61.
28. Sibai BM, Caritis SN, Thom E, Klebanoff M, McNellis D, Rocco L, et al. Prevention of preeclampsia with low-dose aspirin in healthy, nulliparous pregnant women. The National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. New Engl J Med. 1993;329:1213-8.
29. Sibai BM, Hauth J, Caritis S, Lindheimer MD, MacPherson C, Klebanoff M, et al. Hypertensive disorders in twin versus singleton gestations. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. Am J Obstet Gynecol. 2000;182:938-42.
30. Spencer K. Screening for trisomy 21 in twin pregnancies in the first trimester using free beta-hCG and PAPP-A, combined with fetal nuchal translucency thickness. Prenat Diagn. 2000;20:91-5.
31. Than NG, Romero R, Goodman M, Weckle A, Xing J, Dong Z, et al. A primate subfamily of galectins expressed at the maternal-fetal interface that promote immune cell death. Proc Natl Acad Sci USA. 2009;106:9731-6.
32. World Health Organization. Make every mother and child count. World Health Report, 2005. Geneva: World Health Organization; 2005.